Indeed, several studies have identified promising therapeutic targets, such as KDM5A (40), SETDB1/2 (43), or EZH2 (44), that could potentially overcome drug resistance caused by epigenetic mechanisms in SCLC or other tumors. Here, EZH2 is linked to small cell lung carcinoma.